title: Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention.
abstract: BACKGROUND
  This prospective study investigated the association between preprocedural biomarker levels and incident major adverse cardiac events (MACE) in complex patients undergoing percutaneous coronary intervention (PCI) with sirolimus-eluting stenting.
  
  
  OBJECTIVE
  Lipoprotein(a) (Lp[a]), interleukin-10 (IL-10), and high-sensitivity C-reactive protein (CRP) have long-term prognostic value in patients undergoing PCI.
  
  
  METHODS
  Between April 2002 and February 2003, 161 patients were included in the study. Blood was drawn before the procedure, and biomarkers were measured. Patients were followed-up for MACE (death, nonfatal myocardial infarction, and repeat revascularization). Cox proportional hazard models were used to determine risk of MACE for tertiles of biomarkers. Both 1-year and long-term follow-up (median, 6 years; maximum, 8 years) were evaluated.
  
  
  RESULTS
  Mean age was 59 years, and 68% were men. During long-term follow-up, 72 MACE occurred (overall crude cumulative incidence: 45% [95% confidence interval (CI): 37%-52%]). Lp(a) was associated with a higher 1-year risk of MACE, with an adjusted hazard ratio (HR) of 3.1 (95% CI: 1.1-8.6) for the highest vs the lowest tertile. This association weakened and lost significance with long-term follow-up. IL-10 showed a tendency toward an association with MACE. The 1-year HR was 2.1 (95% CI: 0.92-5.0). Long-term follow-up rendered a similar result. The association of CRP with MACE did not reach statistical significance at 1-year follow-up. However, CRP was associated with long-term risk of MACE, with an HR of 1.9 (95% CI: 1.0-3.5).
  
  
  CONCLUSIONS
  In this prospective study, preprocedural Lp(a) level was associated with short-term prognosis after PCI. The preprocedural CRP level was associated with long-term prognosis after PCI.
authors.affiliation: Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands. i.kardys@erasmusmc.nl
authors.forename: Isabella
authors.initials: I
authors.lastname: Kardys
authors.forename: Rohit M
authors.initials: RM
authors.lastname: Oemrawsingh
authors.forename: I Patrick
authors.initials: IP
authors.lastname: Kay
authors.forename: Gregory T
authors.initials: GT
authors.lastname: Jones
authors.forename: Sally P A
authors.initials: SP
authors.lastname: McCormick
authors.forename: Joost
authors.initials: J
authors.lastname: Daemen
authors.forename: Robert Jan
authors.initials: RJ
authors.lastname: Van Geuns
authors.forename: Eric
authors.initials: E
authors.lastname: Boersma
authors.forename: Ron T
authors.initials: RT
authors.lastname: Van Domburg
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D016001:Confidence Intervals; D003324:Coronary Artery Disease / Q000097:blood / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D006305:Health Status Indicators; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D018570:Risk Assessment; D011795:Surveys and Questionnaires; D013997:Time Factors
chemical_list: D015415:Biomarkers; D017270:Lipoprotein(a); D016753:Interleukin-10; D002097:C-Reactive Protein